Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: A multi-centre longitudinal study

A. Barker, A. Lauria, N. Schloot, N. Hosszúfalusi, J. Ludvigsson, C. Mathieu, D. Mauricio, M. Nordwall, B. Van der Schueren, T. Mandrup-Poulsen, W. A. Scherbaum, I. Weets, F. K. Gorus, N. Wareham, R. D. Leslie, P. Pozzilli

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Aims: C-peptide secretion is currently the only available clinical biomarker to measure residual β-cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary considerably dependent upon several variables. We investigated the shape of C-peptide decline over time from type 1 diabetes onset in relation to age at diagnosis, haemoglobin A1c (HbA1c) levels and insulin dose. Methods: We analysed data from 3929 type 1 diabetes patients recruited from seven European centres representing all age groups at disease onset (childhood, adolescence and adulthood). The influence of the age at onset on β-cell function was investigated in a longitudinal analysis at diagnosis and up to 5-years follow-up. Results: Fasting C-peptide (FCP) data at diagnosis were available in 3668 patients stratified according to age at diagnosis in four groups (5years10years18years, n=1655). FCP levels were positively correlated with age (p

Original languageEnglish
Pages (from-to)262-267
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

C-Peptide
Type 1 Diabetes Mellitus
Longitudinal Studies
Fasting
Natural History
Age of Onset
Hemoglobins
Age Groups
Biomarkers
Insulin

Keywords

  • β cell
  • Clinical trial
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Age-dependent decline of β-cell function in type 1 diabetes after diagnosis : A multi-centre longitudinal study. / Barker, A.; Lauria, A.; Schloot, N.; Hosszúfalusi, N.; Ludvigsson, J.; Mathieu, C.; Mauricio, D.; Nordwall, M.; Van der Schueren, B.; Mandrup-Poulsen, T.; Scherbaum, W. A.; Weets, I.; Gorus, F. K.; Wareham, N.; Leslie, R. D.; Pozzilli, P.

In: Diabetes, Obesity and Metabolism, Vol. 16, No. 3, 03.2014, p. 262-267.

Research output: Contribution to journalArticle

Barker, A, Lauria, A, Schloot, N, Hosszúfalusi, N, Ludvigsson, J, Mathieu, C, Mauricio, D, Nordwall, M, Van der Schueren, B, Mandrup-Poulsen, T, Scherbaum, WA, Weets, I, Gorus, FK, Wareham, N, Leslie, RD & Pozzilli, P 2014, 'Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: A multi-centre longitudinal study', Diabetes, Obesity and Metabolism, vol. 16, no. 3, pp. 262-267. https://doi.org/10.1111/dom.12216
Barker, A. ; Lauria, A. ; Schloot, N. ; Hosszúfalusi, N. ; Ludvigsson, J. ; Mathieu, C. ; Mauricio, D. ; Nordwall, M. ; Van der Schueren, B. ; Mandrup-Poulsen, T. ; Scherbaum, W. A. ; Weets, I. ; Gorus, F. K. ; Wareham, N. ; Leslie, R. D. ; Pozzilli, P. / Age-dependent decline of β-cell function in type 1 diabetes after diagnosis : A multi-centre longitudinal study. In: Diabetes, Obesity and Metabolism. 2014 ; Vol. 16, No. 3. pp. 262-267.
@article{be954229e94a4cebbd4c62608beb465c,
title = "Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: A multi-centre longitudinal study",
abstract = "Aims: C-peptide secretion is currently the only available clinical biomarker to measure residual β-cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary considerably dependent upon several variables. We investigated the shape of C-peptide decline over time from type 1 diabetes onset in relation to age at diagnosis, haemoglobin A1c (HbA1c) levels and insulin dose. Methods: We analysed data from 3929 type 1 diabetes patients recruited from seven European centres representing all age groups at disease onset (childhood, adolescence and adulthood). The influence of the age at onset on β-cell function was investigated in a longitudinal analysis at diagnosis and up to 5-years follow-up. Results: Fasting C-peptide (FCP) data at diagnosis were available in 3668 patients stratified according to age at diagnosis in four groups (5years10years18years, n=1655). FCP levels were positively correlated with age (p",
keywords = "β cell, Clinical trial, Type 1 diabetes",
author = "A. Barker and A. Lauria and N. Schloot and N. Hossz{\'u}falusi and J. Ludvigsson and C. Mathieu and D. Mauricio and M. Nordwall and {Van der Schueren}, B. and T. Mandrup-Poulsen and Scherbaum, {W. A.} and I. Weets and Gorus, {F. K.} and N. Wareham and Leslie, {R. D.} and P. Pozzilli",
year = "2014",
month = "3",
doi = "10.1111/dom.12216",
language = "English",
volume = "16",
pages = "262--267",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Age-dependent decline of β-cell function in type 1 diabetes after diagnosis

T2 - A multi-centre longitudinal study

AU - Barker, A.

AU - Lauria, A.

AU - Schloot, N.

AU - Hosszúfalusi, N.

AU - Ludvigsson, J.

AU - Mathieu, C.

AU - Mauricio, D.

AU - Nordwall, M.

AU - Van der Schueren, B.

AU - Mandrup-Poulsen, T.

AU - Scherbaum, W. A.

AU - Weets, I.

AU - Gorus, F. K.

AU - Wareham, N.

AU - Leslie, R. D.

AU - Pozzilli, P.

PY - 2014/3

Y1 - 2014/3

N2 - Aims: C-peptide secretion is currently the only available clinical biomarker to measure residual β-cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary considerably dependent upon several variables. We investigated the shape of C-peptide decline over time from type 1 diabetes onset in relation to age at diagnosis, haemoglobin A1c (HbA1c) levels and insulin dose. Methods: We analysed data from 3929 type 1 diabetes patients recruited from seven European centres representing all age groups at disease onset (childhood, adolescence and adulthood). The influence of the age at onset on β-cell function was investigated in a longitudinal analysis at diagnosis and up to 5-years follow-up. Results: Fasting C-peptide (FCP) data at diagnosis were available in 3668 patients stratified according to age at diagnosis in four groups (5years10years18years, n=1655). FCP levels were positively correlated with age (p

AB - Aims: C-peptide secretion is currently the only available clinical biomarker to measure residual β-cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary considerably dependent upon several variables. We investigated the shape of C-peptide decline over time from type 1 diabetes onset in relation to age at diagnosis, haemoglobin A1c (HbA1c) levels and insulin dose. Methods: We analysed data from 3929 type 1 diabetes patients recruited from seven European centres representing all age groups at disease onset (childhood, adolescence and adulthood). The influence of the age at onset on β-cell function was investigated in a longitudinal analysis at diagnosis and up to 5-years follow-up. Results: Fasting C-peptide (FCP) data at diagnosis were available in 3668 patients stratified according to age at diagnosis in four groups (5years10years18years, n=1655). FCP levels were positively correlated with age (p

KW - β cell

KW - Clinical trial

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84893798821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893798821&partnerID=8YFLogxK

U2 - 10.1111/dom.12216

DO - 10.1111/dom.12216

M3 - Article

C2 - 24118704

AN - SCOPUS:84893798821

VL - 16

SP - 262

EP - 267

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -